Dr. Habal studies the effects of various treatments on patients, primarily in the context of inflammatory bowel disease, cancer, and immune-mediated diseases. He employs innovative techniques like artificial intelligence to analyze clinical notes and detect serious side effects from medications more accurately. His work spans a range of conditions, including advanced colon cancer and Familial Mediterranean Fever, where he examines genetic factors and treatment responses. By improving safety and understanding the complexities of these illnesses, he aims to empower both patients and healthcare professionals in their approach to care.
Key findings
In his study of inflammatory bowel disease, Dr. Habal analyzed 928 clinical notes and identified 703 cases of serious adverse events, with the drug not working as intended being the most common issue.
Using the UCSF-BERT AI model, he achieved an identification accuracy of 88-92% for drug-related side effects, outperforming previous models by 5-10%.
In research on the CancerVax vaccine, he found that patients showing a strong immune response had an average survival time of nearly 22 months compared to others.
Dr. Habal discovered that up to 55% of patients with gastrointestinal carcinoid tumors may develop a second primary malignancy, stressing the importance of monitoring.
In comparing the TA90-IC test to the CEA marker for advanced colon cancer, he found TA90-IC was elevated in 82.9% of patients, showing its potential to improve cancer detection.
Frequently asked questions
Does Dr. Habal study inflammatory bowel disease?
Yes, he focuses on treatment outcomes and safety monitoring for patients with inflammatory bowel disease.
What cancer treatments has Dr. Habal researched?
He has researched the CancerVax vaccine for advanced colon cancer and the optimal use of sentinel lymphadenectomy for breast cancer and melanoma.
Is Dr. Habal's work relevant to patients with Familial Mediterranean Fever?
Yes, he explores the genetic factors affecting the disease's symptoms and treatment outcomes, helping patients with atypical symptoms.
What methods does Dr. Habal use in his research?
He utilizes advanced technology like AI models to analyze clinical notes and improve the identification of adverse treatment effects.
How does Dr. Habal improve patient care?
He enhances understanding of treatment risks and develops better detection methods for complications, thereby guiding patient management.
Publications in plain English
Algorithmic Identification of Treatment-Emergent Adverse Events From Clinical Notes Using Large Language Models: A Pilot Study in Inflammatory Bowel Disease.
2024
Clinical pharmacology and therapeutics
Silverman AL, Sushil M, Bhasuran B, Ludwig D, Buchanan J +13 more
Plain English This study focused on using a new AI model called UCSF-BERT to find serious side effects (SAEs) from outpatient clinical notes for patients with inflammatory bowel disease (IBD) who are treated with a specific medication. The research analyzed 928 clinical notes and identified 703 cases of SAEs, with the most reported issue being the medication not working as intended. UCSF-BERT performed better than other models, accurately identifying drug-related side effects 88-92% of the time, which is 5-10% more accurate than models used before.
Who this helps: This benefits patients with inflammatory bowel disease and their doctors by improving safety monitoring of medications.
Algorithmic identification of treatment-emergent adverse events from clinical notes using large language models: a pilot study in inflammatory bowel disease.
2023
medRxiv : the preprint server for health sciences
Silverman AL, Sushil M, Bhasuran B, Ludwig D, Buchanan J +13 more
Plain English This study examined how well a new language model, UCSF BERT, can find serious side effects from treatments used in patients with inflammatory bowel disease (IBD) by analyzing outpatient clinical notes. The researchers looked at 928 patient notes and found a total of 703 serious adverse events, with the most common being treatments not working effectively. UCSF BERT was better at identifying these issues than other models, achieving an accuracy of 88-92%, which is 5-10% higher than previously used methods. This matters because better detection of treatment-related problems can improve patient safety and care.
Who this helps: Patients receiving treatment for inflammatory bowel disease.
Nonserious infections: should there be cause for serious concerns?
2012
Rheumatic diseases clinics of North America
Dao KH, Herbert M, Habal N, Cush JJ
Plain English This study examined common nonserious infections, such as colds and urinary tract infections, in patients taking specific immune-suppressing medications known as tumor necrosis factor inhibitors (TNFi). Researchers reviewed data from several large trials and found that these infections are prevalent, but the overall impact of TNFi on the severity and outcomes of these infections remains unclear. Understanding these infections is important because it helps doctors manage patient care better while using these treatments.
Who this helps: This research helps patients with immune-mediated diseases and their doctors.
Clinical features and functional significance of the P369S/R408Q variant in pyrin, the familial Mediterranean fever protein.
2010
Annals of the rheumatic diseases
Ryan JG, Masters SL, Booty MG, Habal N, Alexander JD +5 more
Plain English This study investigated two specific genetic changes (P369S and R408Q) in a protein called pyrin that is linked to Familial Mediterranean Fever (FMF), a condition that causes recurrent fevers and inflammation. Out of 22 patients analyzed, only 5 showed clear FMF symptoms, and while 15 were treated with colchicine (a common FMF medication), some others experienced partial relief with other treatments. The findings show that these genetic changes can lead to different symptoms, and that careful interpretation of genetic tests is important for patients showing unusual signs.
Who this helps: This research benefits patients with atypical symptoms of FMF and their doctors in making accurate diagnoses.
The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer.
2001
Seminars in oncology
Habal N, Giuliano AE, Morton DL
Plain English This study looked at a medical procedure called sentinel lymphadenectomy (SLND), which is used to help determine the best treatment for breast cancer and melanoma patients. The researchers found that SLND is a simpler and safer way to check the lymph nodes for signs of cancer compared to traditional methods, and it helps doctors figure out which patients might benefit from additional chemotherapy after surgery. Since knowing the state of the lymph nodes is crucial for patient outcomes, this advancement can lead to better treatment decisions.
Who this helps: This helps cancer patients by guiding personalized treatment plans.
CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer.
2001
Annals of surgical oncology
Habal N, Gupta RK, Bilchik AJ, Yee R, Leopoldo Z +3 more
Plain English This research studied the CancerVax vaccine, which targets advanced colon cancer by triggering the immune system to respond to cancer cells. In a group of 27 patients, those who showed a strong immune response to a specific marker (called IgMTA90) had a significantly longer survival time, with an average of nearly 22 months, compared to others. It’s important because it indicates that CancerVax could potentially improve survival rates for patients with advanced colon cancer, paving the way for new treatments.
Who this helps: This helps patients with advanced colon cancer.
Habal N, Gupta RK, Bilchik AJ, Johnson T, Morton DL
Plain English Researchers studied a new test called TA90-IC to see if it could be a better marker for advanced colon cancer compared to the commonly used CEA marker. They found that TA90-IC was elevated in 82.9% of patients with advanced cancer, compared to 70.2% for CEA, and that using both markers together identified 93.6% of these patients. This is important because it means TA90-IC could help doctors find more cases of advanced colon cancer, which could improve patient care.
Who this helps: Doctors and patients with advanced colon cancer.
Does human melanoma express carcinoembryonic antigen?
2000
Anticancer research
Ravindranath MH, Shen P, Habal N, Soh D, Nishimoto K +4 more
Plain English This study looked at whether a protein called carcinoembryonic antigen (CEA), known to be present in colon cancer, is also found in human skin melanoma cells. The researchers tested different types of cancer cells and found that while CEA was clearly present in colon cancer cells, it was not found in melanoma cells. This distinction is important because it helps clarify the differences between these two types of cancer and could guide diagnostic and treatment decisions.
Who this helps: This helps doctors and researchers understand how to better identify and treat different types of cancer.
Gastrointestinal carcinoid tumors and second primary malignancies.
2000
Journal of surgical oncology
Habal N, Sims C, Bilchik AJ
Plain English This study looked at how often patients with gastrointestinal carcinoid tumors develop other types of cancer, finding that up to 55% of these patients experience a second primary cancer, often involving the gastrointestinal or urinary tract. The researchers believe that certain chemicals released by these tumors might promote the growth of other cancers. Understanding this link is important because it can help doctors monitor and treat patients more effectively.
Who this helps: This information benefits patients with gastrointestinal carcinoid tumors and their doctors.